Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,441.30 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 1,354 shares of the company’s stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $8.45, for a total value of $11,441.30. Following the completion of the sale, the insider directly owned 276,610 shares of the company’s stock, valued at $2,337,354.50. The trade was a 0.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, January 27th, Peter Rahmer sold 11,684 shares of Relay Therapeutics stock. The shares were sold at an average price of $7.62, for a total value of $89,032.08.

Relay Therapeutics Price Performance

NASDAQ RLAY traded up $0.06 on Thursday, reaching $7.71. The company had a trading volume of 1,788,553 shares, compared to its average volume of 2,246,533. Relay Therapeutics, Inc. has a 1 year low of $1.77 and a 1 year high of $9.04. The firm has a 50-day moving average of $7.93 and a 200-day moving average of $5.93. The firm has a market capitalization of $1.34 billion, a PE ratio of -4.41 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). As a group, sell-side analysts expect that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Wells Fargo & Company upgraded Relay Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $6.00 to $13.00 in a research note on Friday, December 12th. Finally, Oppenheimer upgraded shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target for the company in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Key Relay Therapeutics News

Here are the key news stories impacting Relay Therapeutics this week:

• Neutral Sentiment: AAII published an explainer on why RLAY slid ~5.18%, summarizing market reaction and citing recent insider transactions as a driver. AAII Article
• Negative Sentiment: CFO Thomas Catinazzo sold 15,515 shares across Jan. 27–28 (13,820 shares at $7.62 and 1,695 at $8.45), totaling roughly $119k + $14k ? $120k in disclosed sales; ownership fell ~5.22% then 0.68%. SEC filing: Catinazzo SEC Filing
• Negative Sentiment: Insider Peter Rahmer sold 13,038 shares across Jan. 27–28 (11,684 at $7.62 and 1,354 at $8.45), about $89k + $11.4k ? $100k in sales; his holding decreased ~4.03% then 0.49%. SEC filing: Rahmer SEC Filing
• Negative Sentiment: Insider Donald A. Bergstrom sold 21,581 shares across Jan. 27–28 (18,895 at $7.62 and 2,686 at $8.45), about $144k + $22.7k ? $167k in sales; his stake fell ~4.28% then 0.64%. SEC filing: Bergstrom SEC Filing

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. raised its stake in Relay Therapeutics by 130.4% during the 2nd quarter. Franklin Resources Inc. now owns 394,122 shares of the company’s stock valued at $1,364,000 after acquiring an additional 223,042 shares in the last quarter. Congress Asset Management Co. increased its holdings in shares of Relay Therapeutics by 160.9% during the third quarter. Congress Asset Management Co. now owns 408,842 shares of the company’s stock valued at $2,134,000 after purchasing an additional 252,142 shares during the period. Geode Capital Management LLC raised its stake in shares of Relay Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock valued at $11,176,000 after purchasing an additional 159,548 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Relay Therapeutics by 8,553.9% in the second quarter. Farther Finance Advisors LLC now owns 16,702 shares of the company’s stock worth $58,000 after purchasing an additional 16,509 shares during the period. Finally, Acadian Asset Management LLC grew its position in Relay Therapeutics by 16.5% in the 2nd quarter. Acadian Asset Management LLC now owns 794,619 shares of the company’s stock valued at $2,747,000 after buying an additional 112,591 shares in the last quarter. 96.98% of the stock is owned by institutional investors and hedge funds.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.